FRI02 - Industry Sponsored Session Presentation by Wellstat Therapeutics

Description

Urgent Treatment of Early-Onset Severe Toxicity of 5-FU or Capecitabine

OBJECTIVES

• Describe the incidence and burden of early-onset severe toxicity in patients receiving 5-FU and capecitabine

• Describe mechanism of action of 5-FU and its cytotoxic metabolites as it relates to the causes of early-onset severe toxicity

• Recognize signs and symptoms of 5-FU and capecitabine early-onset severe toxicity

• Summarize evidence supporting emergency treatment for patients with early-onset severe toxicity and following 5-FU or capecitabine overdoses

• Review the importance of prompt treatment of overdoses and early-onset severe toxicity

• Educate patients, caregivers, and colleagues about the importance of recognizing and urgently treating early-onset severe toxicity of 5-FU or capecitabine

Speaker:

Alice Beers, BSN, OCN, RN-BC Oncology Nurse Navigator MedStar Georgetown Cancer Network at Washington Cancer Institute MedStar Washington Hospital Center Washington, DC